Nektar Therapeutics Q3 2026 Results: Net Loss of $55.7M, Loss Widens
Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on developing rezpegaldesleukin (NKTR-358) for autoimmune diseases. The company reported a transition to a non-accelerated filer status and continues to incur substantial net losses while relying on collaboration agreements and capital markets for funding.
- Key figure
- Net loss $55.7M